Hereditary Angioedema Therapeutic Market Report by Type (Type I Hereditary Angioedema, Type II Hereditary Angioedema, Type III Hereditary Angioedema), Drug Class (C1-Esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and Others), Treatment Type (Prophylaxis Treatment, On-demand Treatment), Route of Administration (Intravenous, Subcutaneous, Oral), End User (Hospitals, Clinics, Home Healthcare, and Others), and Region 2025-2033

Hereditary Angioedema Therapeutic Market Report by Type (Type I Hereditary Angioedema, Type II Hereditary Angioedema, Type III Hereditary Angioedema), Drug Class (C1-Esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and Others), Treatment Type (Prophylaxis Treatment, On-demand Treatment), Route of Administration (Intravenous, Subcutaneous, Oral), End User (Hospitals, Clinics, Home Healthcare, and Others), and Region 2025-2033

Report Format: PDF+Excel | Report ID: SR112025A5575

Market Overview:

The global hereditary angioedema therapeutic market size reached USD 3.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.9 Billion by 2033, exhibiting a growth rate (CAGR) of 6.82% during 2025-2033.

Report Attribute
 Key Statistics 
Base Year
2024
Forecast Years
2025-2033
Historical Years
2019-2024
Market Size in 2024
USD 3.1 Billion
Market Forecast in 2033
USD 5.9 Billion
Market Growth Rate 2025-2033 6.82%


Hereditary angioedema (HAE) is a rare genetic condition characterized by recurrent episodes of nonpruritic, nonpitting, subcutaneous, and submucosal swelling without the appearance of urticarial lesions. It causes extreme pain, nausea, vomiting, diarrhea, fatigue, muscle ache, tingling, headache, belly pain, hoarseness, and mood changes due to a deficiency of a blood protein. It also leads to fluid leakage due to the constant accumulation of liquids outside the veins of hands, feet, intestinal wall, genitals, face, tongue, and larynx. At present, there is a rise in the demand for hereditary angioedema therapeutics due to the growing advancements in novel therapeutics across the globe.

Hereditary Angioedema Therapeutic Market Trends:

There is presently a considerable increase in the prevalence of HAE among individuals due to a lack of C1 protein. As a result, there is a rise in the demand for HAE therapeutics around the world. This, along with the growing awareness among the masses about the treatment of HAE, represents one of the key factors driving the market. Moreover, key market players are extensively investing in research and development (R&D) activities to enhance orphan drug development. This, coupled with the escalating demand for subcutaneous injections that are highly effective in administering medications, such as insulin, morphine, diacetylmorphine and goserelin, is propelling the growth of the market. In addition, governments of several countries are undertaking initiatives to facilitate faster diagnosis and provide optimal standards of treatment and care to patients. In line with this, rising incidences of genetic mutations leading to the disorder are positively influencing the market. Besides this, the escalating demand for preventive medical care to avoid future illness and treatment is offering lucrative growth opportunities to industry investors. Apart from this, the burgeoning healthcare industry is bolstering the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hereditary angioedema therapeutic market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on type, drug class, treatment type, route of administration and end user.

Breakup by Type:

  • Type I Hereditary Angioedema
  • Type II Hereditary Angioedema
  • Type III Hereditary Angioedema
     

Breakup by Drug Class:

  • C1-Esterase Inhibitor
  • Bradykinin B2 Receptor Antagonist
  • Kallikrein Inhibitor
  • Others
     

Breakup by Treatment Type:

  • Prophylaxis Treatment
  • On-demand Treatment
     

Breakup by Route of Administration:

  • Intravenous
  • Subcutaneous
  • Oral
     

Breakup by End User:

  • Hospitals
  • Clinics
  • Home Healthcare
  • Others
     

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Adverum Biotechnologies Inc., Amgen Inc., Attune Pharmaceuticals, BioCryst Pharmaceuticals Inc., Centogene N.V., CSL Limited, Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Novartis AG, Pharming Group N.V., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Report Coverage:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Segment Coverage Type, Drug Class, Treatment Type, Route of Administration, End User, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Adverum Biotechnologies Inc., Amgen Inc., Attune Pharmaceuticals, BioCryst Pharmaceuticals Inc., Centogene N.V., CSL Limited, Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Novartis AG, Pharming Group N.V., Sanofi S.A. and Takeda Pharmaceutical Company Limited
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report

We expect the global hereditary angioedema therapeutic market to exhibit a CAGR of 6.82% during 2025-2033.

The high prevalence of HAE among individuals owing to the lack of C1 protein, coupled with the growing cases of genetic mutations, are primarily driving the global hereditary angioedema therapeutic market.

The sudden outbreak of the COVID-19 pandemic had led to postponement of elective hereditary angioedema treatments to reduce the risk of the coronavirus infection upon hospital visits and interaction with medical equipment, thereby negatively impacting the global market for hereditary angioedema therapeutics.

Based on the type, the global hereditary angioedema therapeutic market can be divided into type I hereditary angioedema, type II hereditary angioedema, and type III hereditary angioedema. Currently, type I hereditary angioedema holds the majority of the global market share.

Based on the drug class, the global hereditary angioedema therapeutic market has been segregated into C1-esterase inhibitor, bradykinin B2 receptor antagonist, kallikrein inhibitor, and others. Among these, C1-esterase inhibitor currently accounts for the largest market share.

Based on the treatment type, the global hereditary angioedema therapeutic market can be categorized into prophylaxis treatment and on-demand treatment. Currently, on-demand treatment exhibits a clear dominance in the market.

Based on the route of administration, the global hereditary angioedema therapeutic market has been segmented into intravenous, subcutaneous, and oral, where intravenous currently accounts for the largest market share.

Based on the end user, the global hereditary angioedema therapeutic market can be bifurcated into hospitals, clinics, home healthcare, and others. Currently, hospitals hold the majority of the total market share.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Some of the major players in the global hereditary angioedema therapeutic market include Adverum Biotechnologies Inc., Amgen Inc., Attune Pharmaceuticals, BioCryst Pharmaceuticals Inc., Centogene N.V., CSL Limited, Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Novartis AG, Pharming Group N.V., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Hereditary Angioedema Therapeutic Market Report by Type (Type I Hereditary Angioedema, Type II Hereditary Angioedema, Type III Hereditary Angioedema), Drug Class (C1-Esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and Others), Treatment Type (Prophylaxis Treatment, On-demand Treatment), Route of Administration (Intravenous, Subcutaneous, Oral), End User (Hospitals, Clinics, Home Healthcare, and Others), and Region 2025-2033
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials